Abstract：Objective: To study the effect of paclitaxel, Carboplatin combined with Kanglaite on angiogenesis and invasion of cervical cancer patients. Methods: Eighty-seven cervical cancer patients admitted to our hospital from August 2013 to July 2014 were selected and divided into control group (46 cases) and observation group (41 cases) according to the order of inpatient medical records has been successively. The control group was treated with paclitaxel and carboplatin, and the observation group was combined with Kanglaite injection to complete the treatment, 3 weeks for a course of treatment, continuous treatment of 4 courses. The clinical efficacy, tumor microvessel density (MVD), vascular endothelial growth factor (VEGF), immune function, quality of life, and survival were compared between the two groups. Results: After treatment, the total clinical efficacy of the observation group was significantly higher than that of the control group (P<0.05). Before treatment, there was no significant difference in tumor microvessel density (MVD) and vascular endothelial growth factor (VEGF) levels between the two groups (P>0.05). After treatment, the MVD and VEGF levels in the observation group were significantly lower than those in the control group (P<0.05). Before treatment, there was no significant difference in the levels of CD3+, CD4+, and CD8+ between the two groups (P>0.05). After treatment, the levels of CD3+, CD4+, and CD8+ in the observation group were significantly higher than those in the control group (P<0.05). Before treatment, there was no significant difference in somatic function, subjective function, emotional function, social function, and cognitive function scores between the two groups (P>0.05). After treatment, physical function, self-consciousness function, emotional function, social function, and identification in the observation group was significantly higher than that of the control group (P<0.05). The 1-year, 2-year and 3-year survival rates in the observation group were significantly higher than those in the control group (P<0.05). Conclusion: Paclitaxel, carboplatin combined with Kanglaite can regulate angiogenesis in patients with cervical cancer, reduce the invasive ability of cervical cancer cells. It has a good clinical efficacy and good prognosis.
申兴勇,徐昕,袁平,喻召才. 紫杉醇卡铂联合康莱特对宫颈癌患者血管生成及侵袭能力的影响[J]. 河北医学, 2018, 24(12): 2020-2025.
SHEN Xingyong, XU Xin, YUAN Ping, et al. Effect of Paclitaxel and Carboplatin combined with Kang Lai Te on Angiogenesis and Invasion in Patients with Cervical Cancer. HeBei Med, 2018, 24(12): 2020-2025.
[1] Lu Jiaxi,Chen Xiaopin.Therapeutic effect of paclitaxel combined with carboplatin chemotherapy with concurrent intensity-modulated conformal radiotherapy on elderly patients with advanced cervical cancer and its influence on patients' quality of life and immune function[J].Journal of Chongqing Medical University,2018,43(2): 240~244. [2] Chen Yu,Zhou Ying,Zhang Xuefen,et al.Comparative analysis of nedaplatin or cisplatin combined with paclitaxel in adjuvant chemotherapy for cervical cancer[J].Journal of Practical Obstetrics and Gynecology,2015,31(11):862~865. [3] Liu Haixia.The short-term efficacy of paclitaxel combined with carboplatin chemotherapy in the treatment of advanced cervical cancer[J].Shandong Medical Journal,2017,6(6):83~84. [4] Yuan Xiuying,Liu Yanyan,Liu Xiaomei,et al.Effects of paclitaxel and carboplatin combined with radiotherapy in patients with advanced cervical cancer[J].Guangdong Medical Journal,2017,38(S1):242~243. [5] Tang Cuiping,Wu Yang,Zhou Hanjing,et al.Chemotherapeutic effect of Kanglaite injection combined with paclitaxel on human breast cancer cells[J].Chongqing Medical Journal,2016,45(24):3336~3339. [6] Yang Xuening,Wu Yilong.Evaluation criteria of therapeutic effect of solid tumors-RECIST[J].The Journal of Evidence-based Medicine,2004,4(2):85~90,111. [7] Rietbergen MM , van Bokhoven AAJD , Lissenberg-Witte BI , et al. Epidemiologic associations of HPV-positive oropharyngeal cancer and (pre)cancerous cervical lesions[J]. International journal of cancer,2018,143 (2):283~288. [8] Del Mistro A , Adcock R , Carozzi F ,et al. Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more[J]. International journal of cancer, 2018, 143 (2):333~342. [9] Li Fenghu,Yao Feiyue,Chang Jianying,et al.Multicenter randomized clinical trials of synchronous radiotherapy for paclitaxel combined with lobaplatin or cisplatin neoadjuvant chemotherapy for cervical cancer[J].Chinese Journal of Cancer Prevention and Treatment,2016,23(16) : 1090~1094. [10] Chen Xiaoling, Wei Miaocheng. The short-term efficacy of paclitaxel combined with platinum drugs on locally advanced cervical cancer[J].Jiangsu Medical Journal,2013,39(10):1184~1186. [11] Wang Xibo,Ma Lili,Liu Xin.Therapeutic effect of neoadjuvant chemotherapy for paclitaxel combined with nedaplatin for stage IB2~IIB cervical cancer[J].Chinese Journal of Clinical Oncology,2013,40(7):414~416. [12] LIU Shao-xiao,CHENG Xiao-yan,ZHENG Hong-feng,et al.Evaluation of clinical efficacy and safety of paclitaxel plus cisplatin neoadjuvant therapy for locally advanced cervical cancer[J].Chinese Journal of Clinical Pharmacology,2015,31(6):432~434. [13] Lu Jianjun,Zhang Linyan.Efficacy of paclitaxel and cisplatin in the treatment of cervical cancer and its relationship with tissue microvessel and microlymphatic vessel density[J].Chinese Journal of Biochemical Pharmaceutics,2014,34(5):92~94. [14] Xin Shubo,Lin Baihan,Lin Canfeng,et al.Comparison of efficacy of concurrent chemotherapy and chemotherapy with paclitaxel liposome and cisplatin in the treatment of advanced cervical cancer[J].Guangdong Medical Journal,2014,35(5):761~763.
2018, Vol. 24 
冀公网安备13080202000677号